The widely published and experienced team at Buffalo Neuroimaging conducts pre-clinical and all four phases of clinical trials, device trials, and translational research utilizing innovative MRI imaging, Artificial Intelligence, and one of the world's largest MRI scan datasets in MS.
Our specialization in key neurological disease therapeutic areas combined with our academic model means that research sponsors have everyday access to highly-cited scientists in highly collaborative, responsive, and transparent engagements. Our experience and expertise in both therapeutic areas, as well as neuroimaging methodologies, often streamline and strengthen the trial approach.
Buffalo Neuroimaging collaboration begins with your access to our talented team, led by Robert Zivadinov, MD, Ph.D., who has served as Director of the Center since 2003 and continues in his role as Professor of Neurology at the Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo, State University of New York. BNAC researchers have published over 500 peer-reviewed articles with more than 30,000 citations.
We have delivered more than 100 clinical trials, over two-thirds of which advanced our understanding of multiple sclerosis, Parkinson’s disease, and stroke. Other therapeutic areas include transaortic valve replacement (TAVR), atrial fibrillation, concussion, Lupus, cognition, and additional neurological diseases and disorders.
Our real-world translational approaches help determine the predictivity of biomarkers, interactions between the nervous and cardiovascular systems, and their relationship to neurodegenerative disease and aging, as well as clinical, MRI, and genetic correlates.
As important as our investigator-initiated and sponsor-funded trials in specific therapeutic areas, are our pivotal device trials, insights and discoveries in neuroimaging modalities, and continuous development of MRI-PET image acquisition and analysis protocols. We co-develop, execute, and report AI, PET, real-world translational research, biomarkers, and other quantitative bioinformatic studies.
Under Dr. Robert Zivadinov’s leadership, BNAC has secured more than $50 million in funding from a wide variety of sponsors including most of the world’s pharmaceutical leaders, and government agencies including the National Institutes of Health and the U.S. Department of Defense. We enjoy a long history of collaboration with universities in North America, Europe, Australia, and Asia, and partner with CRO organizations worldwide. Our network of 450 research/lab centers spans 60 countries.
BNAC’s commitment to academic integrity is matched by our commitment to quality. We are ISO 9001:2015-certified and our SOPs are compliant with CFR-21 Part 11 and ICH. Disciplined procedures enable BNAC to manage multiple projects with tens of thousands of scans in full compliance with all relevant standards and regulations.
We invite you to learn more about our Core Lab and our pre-clinical capabilities as you determine the most scientifically advanced, time-sensitive, and cost-effective path in moving your research or product development ahead. We look forward to peer-level discussion of the opportunities you are exploring.